R&D channel feed

CRISPR repri­or­i­tizes CAR-T pipeline with cuts, ex­pands in­to au­toim­mune dis­ease as US de­ci­sion for exa-cel looms

Last year
Cell/Gene Tx

An­oth­er Flag­ship-found­ed biotech shut­ters as Ax­cel­la liq­ui­dates, end­ing long Covid plans

Last year
People

Al­to Neu­ro­science un­veils ef­fi­ca­cy sig­nal from PhI­Ia MDD tri­al with ma­chine learn­ing-iden­ti­fied bio­mark­er

Last year

Wet AMD biotech stock soars over 200% as lead as­set match­es Re­gen­eron’s Eylea in PhII test

Last year

At­se­na touts one-year da­ta for con­gen­i­tal eye dis­ease ther­a­py as it seeks part­ner for piv­otal study

Last year
Cell/Gene Tx

UCSF sci­en­tists aim to un­rav­el autism with brain organoids and AI

Last year
AI

Seis­mic rais­es $121M to en­ter im­munol­o­gy space spot­light­ed by ar­genx, Im­muno­vant and oth­ers

Last year
Financing

Apel­lis' eye dis­ease drug gets safe­ty la­bel up­date for rare in­flam­ma­tion side ef­fect

Last year
FDA+

Up­dat­ed: Pfiz­er aban­dons twice-dai­ly GLP-1 ap­proach due to high dis­con­tin­u­a­tion rates, goes back to PhI with once-a-day dose

Last year

Al­tim­mune’s fate turns around af­ter longer look at obe­si­ty tri­al

Last year

Cy­bin gears up for reg­is­tra­tional tri­al of psilo­cy­bin ana­log in ma­jor de­pres­sion af­ter PhII suc­cess

Last year

CRO Fortrea 'dis­putes the ac­cu­ra­cy' of Ace­lyrin's claims about im­munol­o­gy drug tri­al con­duct

Last year
Outsourcing

Xenon of­fers $300M in shares af­ter tout­ing path ahead for MDD pro­gram de­spite PhII miss

Last year
Financing

Ab­b­Vie is gun­ning for ac­cel­er­at­ed ap­proval of an­ti­body-drug con­ju­gate af­ter pos­i­tive PhII da­ta

Last year
Pharma

Ar­ri­vo bags $45M Se­ries B to fund ma­jor de­pres­sion late-stage test and PhII-ready pan­cre­ati­tis as­set

Last year
Financing

Neu­ro start­up stock craters af­ter PhI­II study marred with ‘sig­nif­i­cant de­vi­a­tion’ from tri­al pro­to­col

Last year
Startups

Eli Lil­ly’s Dan Skovron­sky on oral GLP-1, ‘slow­er ramp’ for Alzheimer’s and deals on ‘un­der­ap­pre­ci­at­ed’ as­sets

Last year
People

FDA to make de­ci­sion about Karuna's schiz­o­phre­nia drug by next Sep­tem­ber

Last year
FDA+

Im­muno­vant takes on ar­genx, J&J with plans to test FcRn in­hibitor in mul­ti­ple par­al­lel tri­als af­ter PhI win 

Last year

No­var­tis ex­ecs high­light progress of slim­mer pipeline af­ter San­doz spin­off

Last year
Pharma

Mer­ck stokes pneu­mo­coc­cal ri­val­ry with Pfiz­er, re­veal­ing up­dat­ed 21-va­lent vac­cine da­ta

Last year
Pharma

Novo­cure to lay off 200 work­ers, nar­row pipeline for elec­tric fields can­cer ther­a­py

Last year
People

Bris­tol My­ers bets $100M on Avid­i­ty's RNA ther­a­pies for car­dio­vas­cu­lar dis­eases

Last year
Deals
Pharma

Flag­ship opens hub, plants roots in the UK as gov­ern­ment aims to boost life sci­ence ecosys­tem

Last year
Startups
First page Previous page 59606162636465 Next page Last page
A service from the Financial Times